Inovio Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $65.3K-70.0% YoYTTM through 30 Jun 2026
Net Income -$84.9MTTM through 30 Jun 2026
Free Cash Flow -$80.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -132,871.3% |
| Net Margin | -130,000.0% |
Returns
-352.5%ROE
-114.3%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio1.40x
Net Debt-$58.5Mnet cash position
Cash & Equivalents$31.5M
Quality Metrics
Altman Z-Score-56.20
Piotroski F-Score2 / 9
FCF Margin-123,621.5%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $65.3K
Diluted EPS-$1.03TTMFY2025: $-1.81
Dividend
No dividend
Capital Allocation
R&D Spend$48.5M
Capex Intensity299.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaborative Arrangements | $65.3K | -70.0% | View detailsFuture revenue is highly dependent on regulatory approvals and commercialization of lead candidate INO-3107. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.